• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项随机、双盲、安慰剂对照的初步研究,旨在评估一种新型口服生物黏附制剂治疗非糜烂性反流病相关症状的疗效和耐受性。

A randomized, double-blind, placebo-controlled pilot study to evaluate the efficacy and tolerability of a novel oral bioadhesive formulation for the treatment of nonerosive reflux disease-related symptoms.

机构信息

Department of Medical Sciences, University of Turin, Turin, Italy.

Rajalakshmi Hospital, Vidyaranyapura post.

出版信息

Eur J Gastroenterol Hepatol. 2021 Feb 1;32(2):163-170. doi: 10.1097/MEG.0000000000001888.

DOI:10.1097/MEG.0000000000001888
PMID:32804843
Abstract

OBJECTIVE

The use of antisecretory drugs can provide symptomatic relief in 70-80% of patients suffering from gastro-oesophageal reflux disease (GORD), although this benefit is reduced by 20-30% in the case of nonerosive reflux disease (NERD). The current study evaluates the efficacy and safety of a patented oral formulation (liquid sachets containing hyaluronic acid, a mixture of amino acids including proline, hydroxyl-proline and glutamine, and rice extract dispersed in a bioadhesive polymer matrix) for relieving the symptoms of NERD.

METHODS

A single-centre, randomized, double-blind, parallel group, placebo-controlled clinical study was performed. Patients who experienced at least three episodes of moderate-severity heartburn during the 7-day run-in period were included and treated with three liquid sachets per day for 14 days. The primary objective was to evaluate the proportion of patients with at least a three-point reduction in the total symptom score (TSS).

RESULTS

Overall, 20 patients were randomized to receive the investigational product and 20 to receive the placebo. At the end of treatment, a three-point reduction in the TSS was achieved by 95% of patients treated with the investigational product and by 20% of patients treated with placebo (P < 0.0001). No adverse events were reported.

CONCLUSION

The investigational product showed a statistically significant superiority to the placebo in relieving common symptoms in patients with NERD. Future studies will be aimed at clarifying the hypothesis that this symptomatic benefit is related to the strengthening of the oesophageal barrier against the damage induced by gastric contents.

摘要

目的

抗分泌药物的使用可以为 70-80%的胃食管反流病(GORD)患者提供症状缓解,但在非糜烂性反流病(NERD)中,这种益处会降低 20-30%。本研究评估了一种专利口服制剂(含有透明质酸的液体小袋,一种包含脯氨酸、羟脯氨酸和谷氨酰胺的氨基酸混合物,以及分散在生物粘附聚合物基质中的大米提取物)缓解 NERD 症状的疗效和安全性。

方法

进行了一项单中心、随机、双盲、平行组、安慰剂对照的临床研究。在 7 天的导入期内经历至少 3 次中度至重度烧心发作的患者被纳入并接受每天 3 个液体小袋治疗 14 天。主要目的是评估至少有 3 分总症状评分(TSS)降低的患者比例。

结果

共有 20 名患者随机接受研究产品治疗,20 名患者接受安慰剂治疗。治疗结束时,接受研究产品治疗的患者中有 95%达到 TSS 降低 3 分,而接受安慰剂治疗的患者中只有 20%(P <0.0001)。未报告不良事件。

结论

研究产品在缓解 NERD 患者常见症状方面明显优于安慰剂。未来的研究将旨在阐明这样一个假设,即这种症状缓解与食管屏障对胃内容物引起的损伤的增强有关。

相似文献

1
A randomized, double-blind, placebo-controlled pilot study to evaluate the efficacy and tolerability of a novel oral bioadhesive formulation for the treatment of nonerosive reflux disease-related symptoms.一项随机、双盲、安慰剂对照的初步研究,旨在评估一种新型口服生物黏附制剂治疗非糜烂性反流病相关症状的疗效和耐受性。
Eur J Gastroenterol Hepatol. 2021 Feb 1;32(2):163-170. doi: 10.1097/MEG.0000000000001888.
2
Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.沃克(伏诺拉生)治疗非糜烂性胃食管反流病患者的疗效和安全性评估:一项III期、随机、双盲、安慰剂对照、多中心研究。
Curr Ther Res Clin Exp. 2016 Dec 21;81-82:1-7. doi: 10.1016/j.curtheres.2016.12.001. eCollection 2016.
3
Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study.Vonoprazan 治疗非糜烂性胃食管反流病患者的疗效和安全性:一项随机、安慰剂对照、3 期研究。
Clin Transl Gastroenterol. 2019 Nov;10(11):e00101. doi: 10.14309/ctg.0000000000000101.
4
Fixed combination of hyaluronic acid and chondroitin-sulphate oral formulation in a randomized double blind, placebo controlled study for the treatment of symptoms in patients with non-erosive gastroesophageal reflux.在一项随机、双盲、安慰剂对照研究中,评估透明质酸和硫酸软骨素口服固定复方制剂治疗非糜烂性胃食管反流病患者症状的疗效。
Eur Rev Med Pharmacol Sci. 2013 Dec;17(24):3272-8.
5
Efficacy and safety of Amla (Phyllanthus emblica L.) in non-erosive reflux disease: a double-blind, randomized, placebo-controlled clinical trial.蔓越莓(Phyllanthus emblica L.)在非糜烂性反流病中的疗效和安全性:一项双盲、随机、安慰剂对照临床试验。
J Integr Med. 2018 Mar;16(2):126-131. doi: 10.1016/j.joim.2018.02.008. Epub 2018 Feb 13.
6
Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease.随机临床试验:酸口袋靶向藻酸盐抗酸剂(善卫司双效)缓解上胃肠道症状 - 胃食管反流病的双盲、安慰剂对照、初步研究。
Aliment Pharmacol Ther. 2014 Mar;39(6):595-602. doi: 10.1111/apt.12640. Epub 2014 Jan 28.
7
A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease.一项关于组胺H2受体拮抗剂法莫替丁在日本非糜烂性反流病患者中的随机、双盲、安慰剂对照临床研究。
J Gastroenterol. 2008;43(6):448-56. doi: 10.1007/s00535-008-2186-5. Epub 2008 Jul 4.
8
Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease.随机临床试验:一项双盲、安慰剂对照研究,旨在评估藻酸盐抗酸剂(胃仙-U双重作用)咀嚼片对胃食管反流病患者的临床疗效和安全性。
Eur J Gastroenterol Hepatol. 2019 Jan;31(1):86-93. doi: 10.1097/MEG.0000000000001258.
9
Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease.右兰索拉唑用于缓解有症状的非糜烂性胃食管反流病青少年的烧心症状
Dig Dis Sci. 2017 Nov;62(11):3059-3068. doi: 10.1007/s10620-017-4743-3. Epub 2017 Sep 15.
10
Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial.雷贝拉唑治疗非糜烂性胃食管反流病:一项随机安慰剂对照试验。
Am J Gastroenterol. 2002 Jun;97(6):1332-9. doi: 10.1111/j.1572-0241.2002.05769.x.